AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05727462 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Therapy with TECAR
Description: The following myofascial release techniques will be applied:~Myofascial release of the upper trapezius Gross stretch, vertical gross stretch, and focused stretch of the upper trapezius Myofascial release at the cranial base Gross release of the sternocleidomastoid muscle~Additionally, the following ischemic compression technique will be applied:~Ischemic compression on the upper trapezius muscle Manual therapy manipulations will be administered in combination with a capacitive conventional electrode and two special electrode bracelets that turn the therapist's hands into anti-static electrodes. High-frequency currents will be applied at frequencies of 300 kHz, 500 kHz, and 1 MHz, with a flexible self-adhesive grounding electrode placed on the thoracic spine for reference.
Study NCT05727462 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy without TECAR
Description: Participants in this group will follow the same manual protocol as the first group, without the application of high-frequency current. Each manual therapy session will begin with a ten-minute preparation involving light massage and stretching. The massage will include the effleurage technique, followed by petrissage and kneading, focusing on the cervical and thoracic areas, particularly the upper trapezius, suboccipital region, and cervical paraspinal muscles. Stretching will be applied to the upper trapezius, levator scapulae, and sternocleidomastoid muscles.
Study NCT04416633 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Durvalumab
Description: 500-mg/120-mg IV
Study NCT06048536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 transdermal patch, containing 2.43 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
Study NCT06048536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 transdermal patch, containing 3.64 mg Norelgestromin, will be worn 28 days per cycle with no patch free period.
Study NCT06048536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 28 days per cycle with no patch free period
Study NCT05766787 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Serafilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
Study NCT06048536 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MR-130A-01 Transdermal patch
Description: MR-130A-01 Transdermal patch MR-130A-01 transdermal patch containing 4.86 mg Norelgestromin, will be worn 21 days with a 7-day patch free period.
Study NCT06030427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion and Education
Description: View behavioral educational PowerPoint presentation
Study NCT06030427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet-Based Intervention
Description: Complete virtual behavioral weight management with an integrated mindfulness component program
Study NCT05766787 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Senofilcon A contact lenses
Description: Reusable silicone hydrogel contact lenses worn during the day and removed at night for cleaning and disinfection
Study NCT05853120 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline
Description: Doxycycline is used to treat or prevent infections that are strongly suspected to be caused by bacteria; it is an antimicrobial drug indicated for bacterial infections such as sexually transmitted infections. Doxycycline (DOX) will be given orally at 100 and 200 mg doses.
Study NCT04904575 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block
Description: Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : Levobupivacaïne 2,5mg/ml.
Study NCT04904575 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Erector spinae plane block
Description: Procedure : After installing the sleeping patient and identifying the surgical level by the surgeon, the anesthetist will perform the erector spinae plane block. The anesthetist performs an ultrasound to view the spine and erector muscles and identifies the transverse processes of the vertebra involved in the surgery. Once the location has been made, the anesthetist injects the anesthetic product under ultrasound control between the erector muscle of the spine and its anterior fascia, the trajectory of the needle being thus visualized throughout the procedure. The anesthetist bilaterally injects 3ml/kg of solution with a maximum of 30ml injected.~Drug : NaCL 0,9%.
Study NCT05377203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quadruple combination of half doses therapy→Dual combination of standard dose therapy
Description: Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.~Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.
Study NCT05377203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual combination of standard dose therapy→ Quadruple combination of half doses therapy
Description: Dual combination of standard dose therapy: a single capsule containing dual combination of standard dose of blood pressure medicines (amlodipine besylate tablets 2.5mg×2, irbesartan tablets 75mg×2, metoprolol succinate sustained-release tablets simulator 23.75mg, indapamide tablets simulator 1.25mg), take orally, one capsule once a day.~Quadruple combination of half doses therapy: a single capsule containing quadruple combination of half doses of blood pressure medicines (amlodipine besylate tablet 2.5mg, amlodipine besylate tablet simulator 2.5mg, irbesartan tablets 75mg, irbesartan tablets simulator 75mg, metoprolol succinate sustained-release tablets 23.75mg, indapamide tablets 1.25mg), take orally, one capsule once a day.
Study NCT06030427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Ancillary studies
Study NCT06030427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbit
Study NCT06030427 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Relaxation
Description: Complete mindfulness components
Study NCT06030427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Performance Testing
Description: Ancillary studies
Study NCT06030427 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05278988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS Regimen V
Description: PRS Regimen V(bedaquiline, delamanid, clofazimine, pyrazinamide)
Study NCT05278988 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MDR-TB Treatment Regimen(WHO)
Description: Treatment according to WHO MDR-TB treatment guidelines (2019)
Study NCT06401005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cadonilimab (AK104)
Description: 8Gy\*3 SBRT to irradiate the primary lesion (without axillary lymph node metastasis) or 6Gy\*3 SBRT irradiation to irradiate the primary lesion and axillary lymph node metastasis will be administered at first. And then the first cycle of chemotherapy+AK104 given within 24 hours of the end of SBRT. The total eight cycles of preoperative chemotherapy combined with immunotherapy were administered. Surgical resection was performed within 4-6 weeks after the completion of the eighth cycle of chemotherapy combined with immunotherapy. The chemotherapy regimen consisted of: Four cycles of doxorubicin 50mg/m2 (Q3W) + cyclophosphamide 600mg/m2 (Q3W) were administered, followed by four cycles of sequential albumin paclitaxel (125 mg/m2, d1, d8) and carboplatin (AUC=6, d1, Q3W) for 4 cycles. Postoperative completion of 9 cycles of immunotherapy was continued ± the need for postoperative adjuvant radiotherapy was confirmed based on the patient's preoperative status.
Study NCT05766787 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CLEAR CARE
Description: Hydrogen peroxide based contact lens cleaning and disinfecting solution
Study NCT05753982 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Kinesiotape placement
Description: Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
Study NCT05753982 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotape placement
Description: Placement of kinesiotapes, using ligament techniques on the injured side of chest, focusing on the point of maximal pain.
Study NCT05274191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib Maleate
Description: Pyrotinib ± standard regimen Pyrotinib: 400 mg/day (once a day, orally at the same time every day), continued until disease progression;
Study NCT06419621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PM8002
Description: PM8002 20 mg/kg via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle
Study NCT06419621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
Study NCT06419621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 100mg/m2 via IV infusion on Days 1, 8, and 15 of each 28-day cycle
Study NCT06419621 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 20 mg/kg via IV infusion on Days 1 and 15 of each 28-day cycle
Study NCT05980793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PIP joint denervation
Description: Surgical denervation of the PIP joint
Study NCT05980793 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Patient education plus exercise
Description: An education plus exercise program
Study NCT04639947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EyeCheck
Description: EyeCheck is a newly developed device to provide intraocular pressure (IOP) measurements of the eyes.
Study NCT04639947 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Tonometer (Goldmann and Tonopen)
Description: Standard of care intraocular pressures will be taken using the Goldmann and Tonopen to compare to the EyeCheck.
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo PET/CT and/or CT
Study NCT06238648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Given SC
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT06238648 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT06238648 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT04436029 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Descartes 11
Description: Car T-cells
Study NCT06406140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niacin tablets 500 mg
Description: tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis
Study NCT05413928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Eating- late
Description: Eating window will be 10 hours or less, starting 3 hours after waking up. Same monitoring as Baseline phase.
Study NCT05413928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Eating- early
Description: Eating window will be 10 hours or less, starting 30 min after waking up. Same monitoring as Baseline phase.
Study NCT05413928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time Restrictive Eating- early with early caloric intake
Description: Same as TRE-early, but concentrating caloric intake early in the eating window Same monitoring as Baseline phase.
Study NCT05413928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Macronutrient-controlled meals
Description: Meals with a determined amount of protein, carbohydrates, and fat.
Study NCT05274191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard regimen
Description: standard regimen
Study NCT03918577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Caloric Vestibular Stimulation
Description: Cold water creates a convection current in the semicircular canal of the vestibular apparatus, leading to brief (\<3 min) and typically well tolerated sense of rotational movement. Similar stimulation is routinely used in standard vestibular diagnostic testing.
Study NCT05476536 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-management skills and healthy technology APP
Description: self-management skills and healthy technology APP
Study NCT06550687 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cancer patients' preferences regarding genetic information modalities prior to theranostic exome analysis
Description: Phase 1: Observation of doctor-patient consultations Phase 2: Adaptation of information tools Phase 3: Assessment of understanding of information tools
Study NCT04587791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 400mg Cannabidiol
Description: Participants will receive 400mg
Study NCT04587791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 800mg Cannabidiol
Description: Participants will receive 800mg
Study NCT04587791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1200mg Cannabidiol
Description: Participants will receive 1200mg
Study NCT04587791 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Participants will receive saline
Study NCT05654649 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9%sodium chloride
Description: Patients received 5 ml of IV normal saline as a placebo just before spinal anesthesia
Study NCT05654649 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients received IV dexamethasone 8 mg in 5ml normal saline 0,9%, just before spinal anesthesia.
Study NCT05576662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nirmatrelvir
Description: Two 150 mg tablets taken by mouth every 12 hours
Study NCT05576662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two tablets containing placebo matching nirmatrelvir taken by mouth every 12 hours
Study NCT05576662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: One 100 mg capsule taken by mouth every 12 hours
Study NCT05576662 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ritonavir
Description: One 100 mg capsule taken by mouth every 12 hours
Study NCT06180356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib oral tablets
Description: Niraparib 300 or 200 mg according to body weight or platelet count. Tablets will be taken orally, once daily, continuously (in 28-day cycles).
Study NCT04942054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1
Description: Dose escalation cohort
Study NCT04942054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2
Description: Pharmacodyanamic (PD) dose exploration cohorts
Study NCT04942054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 3
Description: Dose expansion at dose(s) ≤ maximum tolerated dose (MTD) cohort
Study NCT05186454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: analgesia
Study NCT05186454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Analgesia
Study NCT05186454 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone, morphine, midazolam
Description: 1 ml containing 2 mg dexamethasone, 50 µg morphine, and 500 µg midazolam
Study NCT05492890 — intervention group
Intervention type: DEVICE
Intervention: Dexcom G6
Description: Continuous glucose monitoring
Study NCT05536466 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bariatric surgery
Description: bariatric surgery
Study NCT05617339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I am (internet approach to migraine)
Description: I AM has a biopsychosocial perspective. Modules 1-3 and 10 are mandatory and for those who are in need of shorter support and module 1-10 is for those who have more frequent and severe migraines and want a long time of support and treatment. The rationale of the treatment assumes that we do not know why we get migraines and instead focus on becoming as good as possible at managing the migraine attacks. The focus area of the treatments cognitive-behavioral interventions is, among other things, psychoeducation, what migraine is and what happens in the body during migraines and pain, interpretation of symptoms and information processing, training to stop through mindfulness and becoming aware of assumptions that guide behavior during pain management, management of grief, worry, guilt and feelings of shame based on self-compassion, challenging avoidances in a valued direction through ACT interventions and physiotherapist-led cardio training and exercises.
Study NCT05196594 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: collection of stools for genetic analysis
Description: Intestinal microbiome analysis
Study NCT03897998 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naloxone
Description: 4mg of Naloxone will be administered (0.1 mL of 40 mg/ml naloxone solution given intranasally).~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.
Study NCT03897998 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: Intranasal Normal Saline (0.1 mL 0.9% sodium chloride) will be administered shortly before beginning the fMRI experiment.~A random allocation sequence will be independently generated by the UM Pharmacy. The Principal investigator will call for each experiment.
Study NCT05997758 — intervention group
Intervention type: OTHER
Intervention: SEEG stimulation
Description: Electrodes already implanted in patient's anterior insula will be stimulated below the patient-specific threshold at which a seizure was induced. This stimulations will coincide with certain trials in the adaptation task.
Study NCT05997758 — intervention group
Intervention type: BEHAVIORAL
Intervention: Adaptation task
Description: Participants will perform a task that requires them to learn and correctly respond to outliers of two sorts; inconsequential outliers, which require no action, and outliers that are relevant to the course of stimuli and outcomes in future trials, requiring adaptive action.
Study NCT05068024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FWD1509 MsOH
Description: FWD1509 MsOH is administered orally once daily. The starting dose is 10 mg/day for dose-escalation phase, and the dose level to be investigated in the expansion study will depend on the emerging data. For dose-extension phase, the recommended Phase 2 dose will be administered.
Study NCT06407271 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAD/CAM custom ZrO2 healing abutment
Description: Application of custom, zirconium-dioxide healing abutment, fabricated with computer aided design and manufacturing, following immediate implantation.